Loading…
Loading…
Investigator-initiated study led by Dr. Larry Greenbaum of Emory University to evaluate once-daily oral powder TTI-0102, designed to improve adherence San Diego, California--(Newsfile Corp. - October 22, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQB: TTIPF) ("Thiogenesis" or the "Company") today announced that the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug ("IND") application for TTI-0102 in nephropathic cystinosis. On October 16, 2026, the FDA issued a "Study May Proceed" letter for IND 184780.
SPRING, Texas, Sept. 30, 2026 /PRNewswire/ -- TETRA Technologies, Inc. (NYSE: TTI) will release Third Quarter 2026 results after the market closes on November 2, 2026 and will host a conference call to discuss the results and outlook on November 3, 2026, at 10:00am ET.
Valaris (NYSE: VAL - Get Free Report) and Tetra Technologies (NYSE: TTI - Get Free Report) are both energy companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends and earnings. Profitability This table compares Valaris and Tetra Technologies' net
MIND Technology (NASDAQ: MIND - Get Free Report) and Tetra Technologies (NYSE: TTI - Get Free Report) are both small-cap energy companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, dividends, earnings and analyst recommendations. Insider and Institutional Ownership 9.8% of MIND
San Diego, California--(Newsfile Corp. - September 21, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQB: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biopharmaceutical company developing sulfur-based therapeutics for serious pediatric diseases, today announced the results of its Annual and Special Meeting of Shareholders ("Meeting") held on September 8, 2026, and provided a corporate update highlighting recent clinical, regulatory, and financial milestones. Meeting Results All items of business put before shareholders at the Meeting were approved by the requisite majority of votes cast.
Tetra Technologies is an interesting investment opportunity, given the sizable share price pullback and its potential for growth in the next few years. TTI's innovations and services are poised for increased demand as the industry tackles harder-to-recover reserves and aging fields. Despite 8% revenue growth in Q2, net income declined 10%, but interest expense remains comfortably low at 1.8% of revenues.
San Diego, California--(Newsfile Corp. - September 3, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQB: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing sulfur-based therapeutics for rare diseases, today announced that it has engaged Brisco Capital Partners Corp. ("Brisco") to provide investor relations services. Brisco will assist the Company in expanding communications with shareholders, investors and the broader investment community to increase awareness of Thiogenesis and its development programs.
SPRING, Texas, Sept. 2, 2026 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE: TTI) announced that Brady Murphy, Chief Executive Officer, and Kurt Hallead, Treasurer and VP of Investor Relations, will be meeting with institutional investors at the following conferences: September 9, 2026: Barclays 40th Annual Energy-Power Conference (NY, NY) September 10, 2026: Jefferies Renewables, Clean Energy and E&C Conference (NY, NY) TETRA's most recent presentation is available on its Investor Relations site.